Compare CVS Health Corp (CVS) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs 22nd Century Group Inc — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: CVS Health Corp is far larger — about 180626.4× 22nd Century Group Inc's market cap, and CVS Health Corp pays a 3.03% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and 22nd Century Group Inc for 32 Days on average.
| CVS | XXII | |
|---|---|---|
Market Cap | $112.29B | $621.67K |
Volume | 7,763,676 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $110.60 | $483.00 |
52-Week Low | $70.08 | $0.80 |
Typical Hold Time | 83 Days | 32 Days |
Enterprise Value | $174.64B | -$3.69M |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, down 0.17% with a bearish technical signal. The company shows strong revenue growth to $402.1B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus is overwhelmingly bullish with 85% buy ratings and a $111.20 price target representing 27% upside. Recent news highlights Aetna's 2027 Medicare plan enhancements and quarterly dividend declarations.
CVS presents a compelling value opportunity with attractive valuation metrics (P/E 23.17, P/S 0.27) and strong analyst support. Key risks include reimbursement pressure, regulatory scrutiny from ongoing investigations, and declining net margins. The stock's current technical weakness contrasts with solid fundamentals and positive earnings momentum.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
